Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation
Clinical Trials Sunday, April 8th, 2012A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy
Crc.ahajournals.org: Feb. 28, 2012.
Abstract
Background—Cardiac biomarkers are strong predictors of adverse outcomes in several patient populations. We evaluated the prevalence of elevated troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and their association to cardiovascular events in atrial fibrillation (AF) patients in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Read More
